Synthesis of (1R,2S)-1-Amino-2-vinylcyclopropanecarboxylic Acid Vinyl-ACCA) Derivatives: Key Intermediates for the Preparation of Inhibitors of the Hepatitis C Virus NS3 Protease
Authors:
- Pierre L. BeaulieuPBPierre L. Beaulieu
- James GillardJGJames Gillard
- Murray D. BaileyMBMurray D. Bailey
- Colette BoucherCBColette Boucher
- Jean-Simon DuceppeJDJean-Simon Duceppe
- Bruno SimoneauBSBruno Simoneau
- Xiao-Jun WangXWXiao-Jun Wang
- Li ZhangLZLi Zhang
- Karl GrozingerKGKarl Grozinger
- Ioannis HoupisIHIoannis Houpis
- Vittorio FarinaVFVittorio Farina
- Heidi HeimrothHHHeidi Heimroth
- 17 June 2005
- journal article
- research article
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 70 (15) , 5869-5879
Abstract
(1R,2S)-1-Amino-2-vinylcyclopropanecarboxylic acid (vinyl-ACCA) is a key building block in the synthesis of potent inhibitors of the hepatitis C virus NS3 protease such as BILN 2061, which was recently shown to dramatically reduce viral load after administration to patients infected with HCV genotype 1. We have developed a scalable process that delivers derivatives of this unusual amino acid in >99% ee. The strategy was based on the dialkylation of a glycine Schiff base using trans-1,4-dibromo-2-butene as an electrophile to produce racemic vinyl-ACCA, which was subsequently resolved using a readily available, inexpensive esterase enzyme (Alcalase 2.4L). Factors that affect diastereoselection in the initial dialkylation steps were examined and the conditions optimized to deliver the desired diastereomer selectively. Product inhibition, which was encountered during the enzymatic resolution step, initially resulted in prolonged cycle times. Enrichment of racemic vinyl-ACCA through a chemical resolution via diastereomeric salt formation or the use of forcing conditions in the enzymatic reaction both led to improvements in throughput and the development of a viable process. The chemistry described herein was scaled up to produce multikilogram quantities of this building block.Keywords
This publication has 38 references indexed in Scilit:
- Structure−Activity Study on a Novel Series of Macrocyclic Inhibitors of the Hepatitis C Virus NS3 Protease Leading to the Discovery of BILN 2061Journal of Medicinal Chemistry, 2004
- An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virusNature, 2003
- Macrocyclic Inhibitors of the NS3 Protease as Potential Therapeutic Agents of Hepatitis C Virus InfectionAngewandte Chemie International Edition, 2003
- Hepatitis C virus NS3 serine protease as a drug discovery targetDrugs of the Future, 2003
- Advances in therapy for hepatitis C infectionMicrobes and Infection, 2002
- Therapies for Hepatitis C Infection: Targeting the Non-Structural Proteins of HCVCurrent Medicinal Chemistry - Anti-Infective Agents, 2002
- Epidemiology of Hepatitis C: Geographic Differences and Temporal TrendsSeminars in Liver Disease, 2000
- Options de traitement pour les patients atteints d’hépatite C chroniqueCanadian Journal of Public Health, 2000
- Hepatitis CThe Lancet, 1998
- Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis GenomeScience, 1989